<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106690</url>
  </required_header>
  <id_info>
    <org_study_id>CR017032</org_study_id>
    <secondary_id>28431754DIA3012</secondary_id>
    <nct_id>NCT01106690</nct_id>
  </id_info>
  <brief_title>The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Pioglitazone Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of 2 different doses of
      canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are
      receving treatment with metformin and pioglitazone and have inadequate glycemic (blood sugar)
      control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Canagliflozin is a drug that is being tested to see if it may be useful in treating patients
      diagnosed with type 2 diabetes mellitus (T2DM). This is a randomized (study drug assigned by
      chance), double-blind (neither the patient or the study doctor will know the name of the
      assigned treatment), parallel-group, 3-arm (3 treatment groups) multicenter study to
      determine the efficacy, safety, and tolerability of canagliflozin (100 mg and 300 mg)
      compared to placebo (a capsule that looks like all the other treatments but has no real
      medicine) in patients with T2DM who are not achieving an adequate response from current
      antihyperglycemic therapy with metformin and pioglitazone to control their diabetes.
      Approximately 360 patients with T2DM who are receiving combination therapy with metformin and
      pioglitazone will receive the addition of once-daily treatment with canagliflozin (100 mg or
      300 mg) or placebo capsules for 26 weeks followed by a 26-week extension period where
      patients treated with canagliflozin (100 mg or 300 mg) will continue treatment for an
      additional 26 weeks and patients treated with placebo will be switched to active double-blind
      treatment with sitagliptin 100 mg, an antihyperglycemic agent administered once-daily for 26
      weeks. In addition, all patients will take protocol specified stable doses of metformin and
      pioglitazone along with assigned study drug for the duration of the study. Patients will
      participate in the study for approximately 59 to 78 weeks. During the study, if a patient's
      fasting blood sugar remains high despite treatment with study drug, the patient will receive
      treatment with glimepiride (rescue therapy) in accordance with local prescribing information.
      During treatment, patients will be monitored for safety by review of adverse events, results
      from laboratory tests, 12-lead electrocardiograms (ECGs), vital signs measurements, body
      weight, physical examinations, and self-monitored blood glucose (SMGB) measurements. The
      primary outcome measure in the study is the effect of canagliflozin relative to placebo on
      hemoglobin A1c (HbA1c) after 26 weeks of treatment. Study drug will be taken orally (by
      mouth) once daily before the first meal each day unless otherwise specified. Patients will
      take single-blind placebo capsules for 2 weeks before randomization. After randomization,
      patients will take double-blind canagliflozin (100 mg or 300 mg) for 52 weeks OR placebo for
      26 weeks switched to double-blind sitagliptin 100 mg for 26 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7% at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>The table below shows the percentage of patients with HbA1c&lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment (HOMA2-%B) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>HOMA2-%B is a measure of beta cell function (the cells in the pancreas that produce and store insulin). The table below shows the least-squares (LS) mean change in HOMA2-%B from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.</description>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <description>One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.</description>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>The patient's stable dose of metformin background therapy should be continued throughout the study.</description>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>The patient's stable dose of pioglitazone background therapy should be continued throughout the study.</description>
    <arm_group_label>Placebo/Sitagliptin</arm_group_label>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM and be currently treated with PPAR gamma
             agent ((pioglitazone or rosiglitazone) and another anti-diabetes agent (metformin)

          -  Patients in the study must have a HbA1c between &gt;=7 and &lt;=10.5% and a fasting plasma
             glucose (FPG) &lt;270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  or a severe hypoglycemic episode within 6 months before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wes Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bartow</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Prairie</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Selah</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bathurst</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Falls-Windsor</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Drummondville</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pearl</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Truro</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bondy Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Le Creusot</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Narbonne Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuwied</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schkeuditz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessalonikis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgaum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Juarez</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almer√≠a</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Antrim</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Ireland</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <results_first_submitted>April 2, 2013</results_first_submitted>
  <results_first_submitted_qc>April 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2013</results_first_posted>
  <disposition_first_submitted>March 30, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2012</disposition_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canagliflozin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Sitagliptin (Januvia)</keyword>
  <keyword>Metformin</keyword>
  <keyword>Pioglitazone (Actos)</keyword>
  <keyword>Hemoglobin A1c</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated the efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin and pioglitazone. The study was conducted between 13 April 2010 and 20 November 2011 and recruited patients from 74 study centers in 11 countries worldwide.</recruitment_details>
      <pre_assignment_details>344 patients were randomly allocated to the 3 treatment arms. 342 patients received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set (used for the Week 26 efficacy analysis) and safety analysis set (used for the Week 26 and Week 52 safety analyses).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Sitagliptin</title>
          <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
        </group>
        <group group_id="P2">
          <title>Canagliflozin 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
        </group>
        <group group_id="P3">
          <title>Canagliflozin 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Period: Baseline to Week 26</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Creatinine or eGFR withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to take rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of efficacy on rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period: Week 26 to Week 52</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90">1 pt completed core but did not enter ext: physician decision(1).</participants>
                <participants group_id="P2" count="103">1 pt completed core but did not enter ext: physician decision(1).</participants>
                <participants group_id="P3" count="96">5 pts completed core but did not exter ext: lost to f/u(1), not spec(2), AE(1), eGFR criteria(1).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to take rescue therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Sitagliptin</title>
          <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
        </group>
        <group group_id="B2">
          <title>Canagliflozin 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
        </group>
        <group group_id="B3">
          <title>Canagliflozin 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="114"/>
            <count group_id="B4" value="342"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="9.56"/>
                    <measurement group_id="B2" value="56.7" spread="10.36"/>
                    <measurement group_id="B3" value="57" spread="10.19"/>
                    <measurement group_id="B4" value="57.4" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FINLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GREECE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>THAILAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.069"/>
                    <measurement group_id="O2" value="-0.89" spread="0.069"/>
                    <measurement group_id="O3" value="-1.03" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.095</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.811</ci_lower_limit>
            <ci_upper_limit>-0.437</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.096</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.951</ci_lower_limit>
            <ci_upper_limit>-0.575</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7% at Week 26</title>
        <description>The table below shows the percentage of patients with HbA1c&lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7% at Week 26</title>
          <description>The table below shows the percentage of patients with HbA1c&lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.26</ci_lower_limit>
            <ci_upper_limit>4.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.73</ci_lower_limit>
            <ci_upper_limit>10.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.54" spread="2.785"/>
                    <measurement group_id="O2" value="-26.8" spread="2.796"/>
                    <measurement group_id="O3" value="-33.2" spread="2.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-29.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.857</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.96</ci_lower_limit>
            <ci_upper_limit>-21.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-35.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.861</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.30</ci_lower_limit>
            <ci_upper_limit>-28.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment (HOMA2-%B) From Baseline to Week 26</title>
        <description>HOMA2-%B is a measure of beta cell function (the cells in the pancreas that produce and store insulin). The table below shows the least-squares (LS) mean change in HOMA2-%B from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment (HOMA2-%B) From Baseline to Week 26</title>
          <description>HOMA2-%B is a measure of beta cell function (the cells in the pancreas that produce and store insulin). The table below shows the least-squares (LS) mean change in HOMA2-%B from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>HOMA2-%B</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.833"/>
                    <measurement group_id="O2" value="15.19" spread="1.809"/>
                    <measurement group_id="O3" value="18.14" spread="1.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>14.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.521</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.315</ci_lower_limit>
            <ci_upper_limit>19.236</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>17.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.509</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.293</ci_lower_limit>
            <ci_upper_limit>22.166</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.3"/>
                    <measurement group_id="O2" value="-2.8" spread="0.3"/>
                    <measurement group_id="O3" value="-3.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-2.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>-2.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="1.033"/>
                    <measurement group_id="O2" value="-5.30" spread="1.036"/>
                    <measurement group_id="O3" value="-4.70" spread="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-4.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.430</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.879</ci_lower_limit>
            <ci_upper_limit>-1.251</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-3.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.433</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.281</ci_lower_limit>
            <ci_upper_limit>-0.643</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="4.1"/>
                    <measurement group_id="O2" value="3.2" spread="4.1"/>
                    <measurement group_id="O3" value="-1.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-12.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-16.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.1</ci_lower_limit>
            <ci_upper_limit>-5.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Sitagliptin</title>
            <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.4"/>
                    <measurement group_id="O2" value="7.2" spread="1.3"/>
                    <measurement group_id="O3" value="8.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>6.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the duration of study (52 weeks).</time_frame>
      <desc>The total number of adverse events listed in the &quot;Other (non-Serious) Adverse Events&quot; table are based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any treatment arm either during the 26-week period or entire 52-week period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo/Sitagliptin: Baseline to Week 26</title>
          <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E2">
          <title>Canagliflozin 100 mg: Baseline to Week 26</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E3">
          <title>Canagliflozin 300 mg: Baseline to Week 26</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E4">
          <title>Placebo/Sitagliptin: Baseline to Week 52</title>
          <description>Each patient received matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients were switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E5">
          <title>Canagliflozin 100 mg: Baseline to Week 52</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 52.</description>
        </group>
        <group group_id="E6">
          <title>Canagliflozin 300 mg: Baseline to Week 52</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone. Data are presented for Baseline to Week 52.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.1 / 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1 / 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52. In the Week 26 study report, 2 patients had hypoglycaemia recorded in error by the investigator, which were corrected in the Week 52 study report.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>MEDDRA 14.1 used for Week 26/MEDDRA 15.0 for Week 52</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Franchise Medical Leader, Cardiovascular &amp; Metabolism Franchise</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>1-800-526-7736</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

